ARA-290

​ARA-290, also known as cibinetide, is a synthetic peptide originally developed from part of the hormone erythropoietin (EPO). Unlike full EPO, which increases red blood cell production, ARA-290 was designed to target the tissue-protective and anti-inflammatory effects of EPO without significantly affecting red blood cells or raising hematocrit.

Research on ARA-290 has focused on nerve pain, inflammation, and tissue repair. It has been studied for conditions such as small fiber neuropathy, chronic pain, sarcoidosis-related nerve symptoms, and metabolic or inflammatory disorders. The idea behind it is that it may help reduce inflammation, protect nerves from damage, and support healing in tissues under stress or injury.

People interested in performance or recovery sometimes discuss ARA-290 for potential benefits related to recovery, nerve health, reduced pain, or inflammation, but it is not FDA-approved for general medical use. Human research exists, but it is still considered investigational, and long-term safety and effectiveness are not fully established.

​

Benefits

• Relief of neuropathic pain (especially small-fiber neuropathy)

• Strong anti-inflammatory

• Supports nerve repair/regeneration

• Restores immune balance in autoimmune disorders

• Tissue repair actions in injured, stressed, or ischemic tissues

• Provides adjunctive support for metabolic diseases like Type 2 diabetes, helping nerve complications, lipid/glucose improvements

• Does not produce clinically significant changes in electrolytes, liver, kidney, pancreas, erythrocytes, platelets, or leukocytes

• Improves lipid and glucose metabolism in diabetics

​

Possible Side Effects

• Injection site reactions (redness, irritation, soreness)

• Headache

• Nausea

• Dizziness

• Fatigue

• Temporary flu-like feelings

• Changes in blood pressure or heart rate in some people

• Allergic or immune reactions, although uncommon

​

Interactions

• Concomitant use of strong immunosuppressants or biologic anti-inflammatory drugs may amplify immune modulation (caution advised)

• Agents that increase angiogenesis or that affect repair/vascular pathways may theoretically have additive or synergistic effects

• Given the repair/angiogenic axis, close monitoring of anticoagulent and antiplatelet medications is recommended

• Concomitant use of antidiabetic agents may require dose monitoring due to a risk of hypoglycemia

​

Contraindications

• Do not use if you are pregnant or breastfeeding

• Do not use if you determine that you are hypersensitive to this peptide

• Do not use if you have an active malignancy

• Do not use if you have uncontrolled cardiovascular disease or are at high risk of thrombosis